TY - JOUR T1 - Pharmacological treatment of COPD in the on-sint cohort JF - European Respiratory Journal JO - Eur Respir J VL - 44 IS - Suppl 58 SP - P536 AU - Lucía Marín Barrera AU - Cecilia López Ramírez AU - José Luis López-Campos AU - Carmen Calero Acuña AU - Alberto Fernández-Villar AU - Cristina Represas Represas AU - Cristina Ramos Hernández AU - Ricard Casamor Y1 - 2014/09/01 UR - http://erj.ersjournals.com/content/44/Suppl_58/P536.abstract N2 - OBJECTIVE:Describe pharmacological treatment of COPD in patients included in the On-Sint cohort, both when diagnosed and at present.METHODS:Retrospective,multicenter observational study where patient data were collected from single medical visit and by reviewing medicals records.The cohort On-Sint was formed by adult COPD patients,smokers or ex-smokers(≥10 packs-years),who were regularly followed-up by 263 primary care physicians(PC) or 93 Pulmonologists(P).We describe and compare the pharmacological treatment(by therapeutic groups)that patients received upon diagnosis and at present stratified by the GOLD classification.Quantitative data expressed as mean(standard deviation)RESULTS:1214 patients met inclusion criteria(age of 66.4(9.7)years,78.7% male,857(70.6%)by PC).The average time interval from diagnosis to inclusion was 8(7.2)years.The different therapeutic group that each patient received upon diagnosis and at present according to 2010 GOLD stages,is indicated in the table.View this table:CONCLUSIONS:On-Sint cohort has detected an increase in the use of LABD and ICS,although the indication seems to be more consistent with the functional severity.Mucolytics are still excessively used.The use of all groups of treatment is lower for those with unknown GOLD stage. ER -